In a notable development, Clearmind Medicine Inc, a biotech company dedicated to discovering and developing novel psychedelic-derived therapeutics to address under-treated health problems, has disclosed positive results in cocaine addiction treatment. The company’s groundbreaking treatment, specifically designed for cocaine addiction, hinges on its innovative psychedelic molecule, MEAI, representing a significant milestone in the ongoing battle against addiction.
The recent announcement of positive results in addiction treatment has sparked a notable surge in the stock value of Clearmind Medicine. The company’s stock, which concluded Monday’s trading session at $3.83, experienced a substantial increase, initiating Tuesday’s trading at $5.86.
At the time of this publication, Clearmind Medicine Inc stock (CMND) has witnessed a surge.
Clearmind Medicine Inc
Current Price: $5.75
Change : +1.92
Change (%): (50.00%)
Volume: 35.8M
Source: Tomorrow Events Market Data
The transformative trial, spearheaded by Professor Gal Yadid and his research team at the Gonda Multidisciplinary Brain Research Center within Bar Ilan University in Israel, builds upon a prior experiment indicating a significant reduction in cocaine-induced cravings among rodents treated with MEAI.
Dr. Adi Zuloff-Shani, the CEO of Clearmind Medicine, expressed optimism about the results, stating, “These results, previously announced, offer a beacon of hope, demonstrating the potential efficacy of MEAI in reducing cocaine-related conditions. Our unique psychedelic compound has shown remarkable results in pre-clinical trials for cocaine addiction.” She added, “These promising results from our MEAI-based treatment offer a potential paradigm shift in how we approach the complex challenge of cocaine addiction, an addiction for which no dedicated treatment has yet been developed.”
Clearmind’s innovative approach signifies a transformative leap forward in addressing a global crisis. With millions worldwide grappling with cocaine addiction, the successful application of MEAI has the potential to revolutionize treatment protocols and provide newfound hope to individuals ensnared in the cycle of addiction.
The significant research breakthrough has led to the filing of a patent application in the United States. This development is part of Clearmind Medicine’s ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC), a specialized clinical-stage pharmaceutical company focusing on therapies for central nervous system disorders. The collaboration focuses on combining Clearmind’s MEAI, a novel proprietary psychedelic treatment for addiction, with SciSparc’s CannAmide™. As a component of this collaborative effort, Clearmind has submitted a provisional patent application related to cocaine addiction.
As Clearmind Medicine continues to lead the way in the field of psychedelic medicine, this development underscores the company’s unwavering commitment to unlocking the untapped potential of psychedelic compounds in medical treatment. The positive strides in addiction treatment mark a pivotal moment in the ongoing mission of Clearmind Medicine to provide innovative solutions for those grappling with the challenges of addiction on a global scale.
